CuraTeQ Biologics receives approval for biosimilar Dazublys from UK's MHRA
Earlier in July 2025, Dazublys has received the marketing authorisation in the European Union from the European Commission
Earlier in July 2025, Dazublys has received the marketing authorisation in the European Union from the European Commission
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
Attorney General Ken Paxton sued pharmaceutical giant Eli Lilly for bribing and illegally inducing medical providers to prescribe its most profitable drugs
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs
Subscribe To Our Newsletter & Stay Updated